Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics / Immune Cells in Cancer · Journal article
Acs Applied Bio Materials · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study in a murine model demonstrating that sequential administration of mannose-targeted liposomes carrying resiquimod (to reprogram tumor-associated macrophages) followed by doxorubicin enhances anticancer effect and shows favorable cardiac safety compared to untargeted controls. The work is mechanistically sound and uses immunocompetent animals, but lacks clinical data, human efficacy endpoints, and detailed statistical reporting required to support translation.
Preclinical in vivo study in immunocompetent murine model with in vitro supporting studies. 4T1 murine triple-negative breast cancer-bearing immunocompetent mice; in vitro studies in M2-polarized macrophages and MDA-MB-231 breast cancer cells.. Intervention: Sequential administration: mannose-targeted liposomes encapsulating resiquimod (M-LIPO-RES) followed by mannose-targeted liposomes encapsulating doxorubicin (M-LIPO-DOX).. Compared with: Other treated groups (specific comparators not detailed in source text)..
M-LIPO-RES increased cellular uptake in M2-polarized macrophages and MDA-MB-231 cancer cells, indicating receptor-mediated internalization. Sequential M-LIPO-RES followed by M-LIPO-DOX demonstrated improved anticancer effect in the 4T1 immunocompetent mouse model. M-LIPO-RES induced M2-to-M1 macrophage polarization confirmed by cytokine profile and surface markers (CD206, CD86) both in vitro and in vivo.
No human data; mouse model does not guarantee human TNBC response or safety.
While the sequential immuno-chemotherapy concept is rational and preclinical results are encouraging, clinical translation requires human trials to establish safety, dosing, and efficacy in TNBC patients. Cardiac safety and macrophage repolarization must be validated in human studies before clinical adoption.
Preclinical study in murine tumor model with surrogate endpoints (macrophage polarization, cytokine profile, cardiac markers) and no human data; promising mechanistic approach but requires clinical validation.
As stated by the source record.
Quoted from the source exactly as published.
While the sequential immuno-chemotherapy concept is rational and preclinical results are encouraging, clinical translation requires human trials to establish safety, dosing, and efficacy in TNBC patients. Cardiac safety and macrophage repolarization must be validated in human studies before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Recently, explorations are being undertaken involving chemo-immunotherapy based on targeting cancer cells and tumor-associated macrophages (TAMs). However, these strategies mainly focus on delivering TAM modulators and chemotherapy simultaneously, without considering the effect of chemotherapy on TAMs and which may compromise TAM-modulatory action. This necessitates investigations involving sequential treatment wherein pretreatment would enable efficient M2-to-M1 repolarization before administration of chemotherapy. In this study, mannose-targeted liposomes encapsulating resiquimod (M-LIPO-RES) and doxorubicin (M-LIPO-DOX) were developed to target M2-type TAMs and cancer cells, respectively. The formulations (M-LIPO-RES and M-LIPO-DOX) were characterized for particle size, zeta potential, surface chemistry, morphology, drug entrapment efficiency, release profile, and hemolysis potential. The results showed that mannose-targeted liposomes possess a marked increase in cellular uptake in M2-polarized macrophages and MDA-MB-231 cells, revealing their potential for receptor-mediated cellular internalization. M-LIPO-RES-mediated macrophage polarization from the M2 to M1 phenotype was confirmed by analysis of the cytokine profile and estimation of TAM-associated surface proteins (e.g., CD206 and CD86), both in vitro and in vivo. The biodistribution study indicated the preferential accumulation of the developed formulation at the tumor site following intravenous administration. Furthermore, the anticancer effect was studied in the immunocompetent 4T1 mouse model, which indicated improved anticancer effect after sequential treatment (M-LIPO-RES followed by M-LIPO-DOX). Additionally, cardiac markers (i.e., troponin and CK-MB) were decreased in the targeted formulation group as compared to other treated groups, indicating a favorable cardiac safety profile. The presented targeted nano strategy preserves the immune-modulatory effect and reveals great potential for immuno-chemo response in triple-negative breast cancer (TNBC) therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.